Evidence map›Paper›PMID 40270965›Full record

ArticleFrontiers in immunology2025

Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from LDHC in lung adenocarcinoma.

Ruifang Zhong, Xiaohong Guo, Chuncai Wu, Yangyi Guo, Yanli Kang, Jianbin You, Falin Chen, Qianshun Chen, Liangyuan Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruifang Zhong *Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Xiaohong Guo *Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Chuncai WuDepartment of Clinical Laboratory, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China.
Yangyi GuoDepartment of Clinical Laboratory, The Third Hospital Of LongYan, LongYan, China.
Yanli KangShengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Jianbin YouShengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Falin ChenShengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Qianshun ChenShengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Liangyuan ChenShengli Clinical Medical College of Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lactate dehydrogenase C (LDHC) is a kind of cancer-testis antigen (CTA) that has been reported to be a biomarker for diagnosis, efficacy evaluation, and recurrence monitoring of lung adenocarcinoma (LUAD). This study aims to assess the value of LDHC in peptide-based vaccines for LUAD immunotherapy. Methods: The LDHC recombinant protein was purified and its effect on PC9 cells was evaluated by wound healing assay, Transwell invasion, and migration assay. Ten HLA-A2-restricted LDHC-derived peptides were predicted and synthesized, and the affinity for the HLA-A2 molecule was analyzed by T2 binding assay and molecule docking. Enzyme-linked immunospot (ELISpot) and LDH cytotoxicity assay were performed to determine the interferon-γ (IFN-γ) release level and tumor cell lysis ability of peptide-induced specific cytotoxic T lymphocytes (CTLs). Results: The LDHC recombinant protein promoted invasion and migration of PC9 cells. Three HLA-A2-restricted LDHC-derived peptides P2 (LDHC Conclusions: LDHC may serve as a targetable biomarker for peptide-based immunotherapy of LUAD.

Indexed as

Adenocarcinoma of LungEpitopes, T-LymphocyteHLA-A2 AntigenL-Lactate DehydrogenaseLung NeoplasmsT-Lymphocytes, CytotoxicAntigens, NeoplasmCancer VaccinesCell Line, TumorCytotoxicity, ImmunologicHumansInterferon-gammaAntigens, NeoplasmCancer VaccinesEpitopes, T-LymphocyteHLA-A*02:01 antigenHLA-A2 AntigenInterferon-gammaL-Lactate DehydrogenaseHLA-A2lactate dehydrogenase Clung adenocarcinomapeptidesrecombinant protein

Identifiers

PMID40270965
PMCPMC12014551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.